Trial Profile
A non-interventional study on the tolerability of octagam(R) 5% and octagam(R) 10%
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2016
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Graft-versus-host disease; Immunodeficiency disorders
- Focus Adverse reactions
- Acronyms GammaTrack
- Sponsors Octapharma
- 01 Nov 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics.
- 10 Oct 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics
- 19 Apr 2013 New source identified and integrated (United Kingdom Clinical Research Network record, 13403).